Aminothiadiazole in the Treatment of Advanced Leiomyosarcoma of the Uterine Corpus

Publisher Website
Google Scholar
Abstract
Aminothiadiazole was used to treat 21 patients with metastatic or recurrent leiomyosarcoma of the uterus. All patients received a starting dose of aminothiadiazole of 125 mg/m2 intravenously (30-to-45-minute infusion), which was repeated at weekly intervals. All patients also took allopurinol 300 mg per day orally to prevent hyperuricemia, a side effect of aminothiadiazole. Five patients (25%) had stable disease but there were no objective responses. Toxicity was generally mild with this regimen. There was no life-threatening toxicity and only three episodes of severe toxicity. One patient experienced both grade 3 leukopenia and thrombocytopenia, while another patient had grade 3 nausea and vomiting. Further studies in this disease are not planned.

This publication has 0 references indexed in Scilit: